Abstract
Cancer outcomes vary widely between individual patients, each accumulating an irregular record of treatments, diagnoses, measurements, and complications. Current prognostic models reduce this complexity into a single snapshot, focus on narrow clinical settings, and rarely generalize across hospitals. Here we introduce Chronicle, an explainable transformer that learns from entire patient trajectories to predict diverse clinical outcomes throughout the disease course while capturing both short- and long-term temporal dependencies.
Trained on 53.7 million longitudinal data points from 51,711 patients spanning 67 cancer types, Chronicle operates natively on irregular data without imputation and jointly predicts eight endpoints within a flexible framework adaptable to additional outcomes. Chronicle outperformed cross-sectional models for overall survival prediction (C-index 0.84 vs 0.76-0.79), stratified patients more accurately than established prognostic systems, including TNM stage, and predicted seven adverse event and transfusion endpoints (AUC 0.80-0.92). Applied without retraining to 69,341 patients in Germany, Switzerland, and the United States, Chronicle generalized across healthcare systems and improved further with local fine-tuning. Integrated explainability traced each risk update to patient-specific clinical factors, revealing distinct temporal persistence of prognostic information, with relevance half-lives ranging from weeks for therapies to nearly one year for baseline characteristics.
These findings demonstrate that learning from hospital-wide patient trajectories enables interpretable and continuously updated predictions, providing a scalable framework to support individualized treatment decisions.
Competing Interest Statement
B.H. reports consulting fees from Johnson&Johnson, Bayer, ABX, Astellas, Merck, Amgen, MSD/Pfizer, Novartis, BMS, Monrol, Onkowissen, POINT Biopharma, Ipsen, AstraZeneca, Lightpoint medical, Telix, and Accord Healthcare; travel support from AstraZeneca, BMS, Janssen, Bayer, Pfizer and Ipsen; grants or contracts from Janssen, Deutsche Forschungsgesellschaft, Novartis, and BMS; participation on data safety monitoring boards for Johnson&Johnson and ABX. V.G: Speaker fee: Bristol-Myers Squibb, Ipsen, Eisai, MSD, Merck KGa, AstraZeneca, AAA/Novartis, Amgen, Johnson & Johnson, Teilx Pharmaceuticals, Gilead Sciences, Roche. Consulting fee: Bristol-Myers Squibb, Pfizer, Novartis, MSD, Ipsen, Johnson & Johnson, Eisai, Debiopharm, Gilead Sciences, Oncorena, Synthekine, Recordati. Travel support: Pfizer, Johnson & Johnson, Merck KGa, Ipsen, Amgen. SM: Research funding, advisory board, honorary or travel expenses: AbbVie, AstraZeneca, Clovis, Eisai, GlaxoSmithKline, Gilead, Hubro, Immunogen, MSD, Novartis, Nykode, Olympus, PharmaMar, Pfizer, Regeneron, Roche, Seagen, Sensor Kinesis, Teva J.T.S: receives honoraria as consultant or for continuing medical education presentations from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Immunocore, ioMEDICO, MSD Sharp Dohme, Novartis, Novocure, Roche/Genentech, and Servier. His institution receives research funding from Abalos Therapeutics, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisbach Bio, and Roche/Genentech; he holds ownership in FAPI Holding (< 3%). I.P.: Advisory Board: BeOne, Daiichi Sankyo, Taiho Oncology Europe. Honoraria: Deutsche Bundesbank, neoConnect GmbH, Daiichi Sankyo, Roche Diagnostics, Springer Medizin. The remaining authors declare no competing interests related to this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics Committee of the Medical Faculty of the University of Duisburg-Essen (22-10881-BO). The requirement for written informed consent was waived due to the study's retrospective design and the deidentification of data. Data analysis in Zurich was approved by the Cantonal Ethics committee; BASEC-Nr: 2023-00234, Comprehensive Cancer Center Zuerich (CCCZ) - Data analytics. The study was approved by the Ethics Committee at LMU Munich (23-0650).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Deidentified data are available upon reasonable request. Data cannot be shared with investigators outside the institution without consent. Data access is generally subject to applicable data protection regulations and data use and access regulation onsite. The MIMIC-IV database is available via PhysioNet to credentialed users (https://physionet.org/).
Funder Information Declared
